$CLX

The Clorox Company Q4 2026 Earnings Call Summary

Clorox held its Q4 2026 earnings call, citing value-seeking consumer behavior and inflation pressures. Management said most categories have recovered from a prior cyberattack, with Litter still lagging. It highlighted GOJO acquisition synergies, fiscal 2027 assumptions including Brent at $90/bbl, inflation over $200M, and free cash flow of 11% to 13% of sales.

Original reporting
Published Aug 6, 2026, 12:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 1:12 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
The Clorox Company Q4 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$CLXNeutralMed
01

Why it matters

Traders can update models for 2027 based on the disclosed cost and margin framework: inflationary pressures over $200m, GOJO-related gross margin dilution (0.5 point), interest expense around $210m, and an ERP productivity ramp starting late FY2027 into FY2028. It also highlights product/category execution risks (Litter turnaround, Kingsford weather volatility) and a dividend sustainability narrative tied to rebuilding gross margins and free cash flow generation.

02

Market read

The call summary provides forward-looking guidance inputs (Q1 timing, inflation, Brent, interest expense, FCF range) and integration details (GOJO margin dilution, ERP savings ramp) that can drive near-term expectation revisions.

03

What to watch

Litter turnaround timing (early innings) and weather-driven Kingsford volatility could create category-specific earnings dispersion that is not captured by the headline FCF range.

Relevance 7/10Novelty 6/10Timing: ahead of/into FY2027 positioning after the Q4 2026 earnings call

Background

The piece summarizes Clorox management’s discussion of operational recovery post-cyberattack, GOJO acquisition integration, and the company’s FY2027 outlook assumptions.

Company-level read

Ticker impact

$CLXNeutralMedium confidence
Context

Clorox’s Q4 2026 call summary includes FY2027 guidance assumptions, including a Q1 “blip,” inflation headwinds, and GOJO-driven margin dilution.

Expected impact

Near-term positioning likely hinges on whether the market views the Q1 timing “blip” and inflation assumptions as manageable versus consensus.

Evidence & confidence

The article discloses multiple forward-looking assumptions (inflation >$200m, Brent $90, interest expense ~$210m, FCF 11% to 13%, ERP ramp late FY2027) that can re-rate expectations, but it is a call summary rather than a fresh earnings release with explicit consensus comparison.

Market effects

Household products peers may see read-across on pricing power and inflation pass-through assumptions, especially around commodity and freight cost pressure.

No explicit regional demand shock is described beyond weather volatility affecting Kingsford.

Ocean freight and commodity inflation assumptions could influence broader consumer-staples cost expectations, but the article is company-specific.

Counterpoint

The “blip” in Q1 and higher inflation assumptions may already be priced in; the more important signal is the credibility of the FCF 11% to 13% range and the late-FY2027 ERP savings ramp.

Key entities

  • The Clorox Company

    Discusses Q4 2026 performance context and provides FY2027 guidance assumptions, including inflation, GOJO integration effects, and FCF range.

  • GOJO acquisition

    Management frames GOJO as a driver for health and hygiene platform expansion and B2B synergies, with a different P&L profile and gross margin dilution.

  • Linda Rendle

    CEO transition process underway as she intends to step down for personal health reasons.

Related articles

$CLXMedAI 8/10

Clorox fiscal 2027 outlook: inflation and value shoppers weigh

Clorox forecast a difficult fiscal 2027, citing inflation and consumers shifting to value. The company expects net sales up 13% to 14% for fiscal 2027, with about 9.5 points from its April 2026 GOJO Industries acquisition. Adjusted EPS is projected at $5.70 to $6.00, GAAP diluted EPS $5.41 to $5.71. Q4 revenue fell 2% to $1.95B; adjusted EPS was $1.66.

$CLXMedAI 8/10

Clorox forecasts upbeat annual sales as demand improves

Reuters reports Clorox (Pine-Sol maker) forecast fiscal 2027 net sales growth of 13% to 14%, above analysts’ 12.8% estimate, and adjusted EPS of $5.70 to $6 versus $5.97 expected. Q4 sales fell 2% to $1.95B but beat $1.90B. Gross margin dropped to 41.3%. Clorox cited improving demand amid a challenging cost and value-seeking environment.

$CLXMedAI 8/10

CLOROX CO /DE/ (CLX): Results of Operations and Financial Condition

CLOROX CO /DE/ (CLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-pressreleasedatedaug.htm EX-99.1 Document Clorox Reports Q4 and FY26 Results, Provides FY27 Outlook Delivers Q4 results in line with expectations while advancing strategic investments OAKLAND, California, Aug. 3, 2026 — The Clorox Company (NYSE: CLX) today reporte

$CLXMedAI 9/10

Clorox Announces Leadership Transition as CEO Linda Rendle Prepares to Exit

The Wall Street Journal reported May 28 that Clorox CEO Linda Rendle will step down for health reasons after more than two decades. Clorox said it has started a comprehensive search for a new chief executive, while Rendle will remain in her role. In a blog post, Rendle said she was diagnosed with early-stage breast cancer, is now cancer-free, and cited ongoing treatment side effects.

$KMBLow

Kimberly-Clark vs. The Clorox: Which Consumer Goods Stock Is a Better Buy in 2026?

The article compares Kimberly-Clark (KMB) and The Clorox Company (CLX) as consumer staples for 2026. Kimberly-Clark reported FY2025 revenue near $16.4B (down from $16.8B) and net income about $2.0B; Clorox reported FY2025 revenue near $7.1B (flat) and net income about $810M. It cites higher customer concentration for both (Walmart ~16% for KMB, ~27% for Clorox) and notes KMB is selling tissue operations to Suzano and has a potential $48B merger with Kenvue, while Clorox is recovering from a 2023